Mikael Dolsten,
president of Pfizer Global Research and Development Department in the UBS
Global Life Sciences general meeting on September 20 this year, said: "We
started to pay attention to some core areas, with emphasis on externalization
strategy, including select future CRO partners Union. Acquisition and
cooperation of other biotechnological firms will also be build, establishing a
really strong cooperation network with academia. " In addition, Dolsten
said in its recent speech, Pfizer has terminated about 90 proof-of-concept
stages of the project. Pfizer's current research areas have priority in several
major areas of immunology and inflammation, cancer, cardiovascular disease,
metabolic and endocrine diseases, neuroscience and pain, vaccine, including small
molecules and macromolecular drugs. In addition to reducing the areas of focus
of the disease, Pfizer still re-adjust and reduced its R & D activities,
and outsourced certain functions. For CRO, Pfizer selected 2 (ICON and PAREXEL)
from the original 17 functional service providers as strategic partners of the
clinical trials. Beginning in 2010, Pfizer established Treatment Innovation
Center(CTI). And the center is an opening innovation cooperation model, which
transferred biological treatment methods (antibodies, peptides and proteins)
and other drugs of therapeutic areas into the application of clinical
applications.
Comments:
Lipitor, since the market in 1998, has been the main source of income for
Pfizer. If Pfizer is unable to generate a "blockbuster" mothball
army, it will be difficult to glorious again. However, after the failure of
Torcetrapib, Dimebon, and a series of key drug candidate by experiencing late
clinical trials. Pfizer had to seek the support of an outside laboratory.
Therefore, targeted acquisitions and cooperation to acquire jointly developing
new drugs or the right to operate has become one of the most important
strategies for patent cliff the Pfizer deal with.
| recombinant growth factor |
| bmp 2 |
| M-CSF |
没有评论:
发表评论